Top

Published in:

01-08-2008

Administration of the Rho-Kinase Inhibitor Fasudil Before Ischemia or just After Reperfusion, but not 30 min After Reperfusion, Protects the Stunned Myocardium in Swine

Authors: Itsuko Shibata, Osamu Yoshitomi, Tadasuke Use, Hiroyuki Ureshino, Sungsam Cho, Takuji Maekawa, Tetsuya Hara, Koji Sumikawa

Published in: Cardiovascular Drugs and Therapy | Issue 4/2008

Abstract

Objectives

We assessed the effect of administration time for fasudil treatment of the stunned myocardium in 40 anesthetized open chest swine.

Materials and methods

All swine were subjected to 12 min ischemia followed by reperfusion to generate stunned myocardium. Group A (n = 11) received saline in place of fasudil both before ischemia and after reperfusion. Group B (n = 10) received 30 min intravenous fasudil at a rate of 13 μg/kg/min starting 45 min before ischemia and received saline after reperfusion. Groups C (n = 10) and D (n = 9) received saline before ischemia, and received fasudil at a rate of 13 μg kg⁻¹ min⁻¹ starting just before reperfusion in group C and 30 min after reperfusion in group D. In both groups, treatment lasted 30 min. Myocardial contractility was assessed by percent segment shortening (%SS).

Results and discussion

Three swine in group A, 2 swine in each of groups B and C, and one swine in group D had ventricular fibrillation or tachycardia after reperfusion and were excluded from further analysis. The changes of %SS from baseline at 90 min after reperfusion in groups B and C were 68 ± 8% and 75 ± 8%, respectively, which were significantly higher than in group A or D (47 ± 10% or 43 ± 8%).

Conclusion

We conclude that fasudil administered before ischemia or just after reperfusion, but not 30 min after reperfusion, protects the stunned myocardium.

Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT887 on cerebral vasospasm after aneurismal subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind trial. J Neurosurg. 1992;76:571–7.PubMedCrossRef

Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25:1767–75.PubMedCrossRef

Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003;41:15–9.PubMedCrossRef

Inokuchi K, Ito A, Shimokawa H, et al. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol. 2004;44:275–7.PubMedCrossRef

Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004;24:1842–7.PubMedCrossRef

Demiryürek Ş, Kara AF, Çelik A, et al. Effects of Y-27632, a selective Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. Biochem Pharmacol. 2005;69:49–58.PubMedCrossRef

Sanada S, Asanuma H, Tsukamoto O, et al. Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 2004;110:51–7.PubMedCrossRef

Hamid SA, Bower HS, Baxter GF. Rho-kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol. 2007;292:2598–606.CrossRef

Bolli R, Zughaib M, Li XY, Tang XL, Sun JZ, Triana JF, et al. Recurrent ischemia in the canine heart causes recurrent bursts of free radical production that have a cumulative effect on contractile function. A pathophysiological basis for chronic myocardial “stunning”. J Clin Invest. 1995;96:1066–84.PubMedCrossRef

10.

Kim SJ, Ghaleh B, Kudej RK, Huang CH, Hintze TH, Vatner SF. Delayed enhanced nitric oxide-mediated coronary vasodilation following brief ischemia and prolonged reperfusion in conscious dogs. Circ Res. 1997;81:53–9.PubMed

11.

Sun JZ, Tang XL, Park SW, Qiu Y, Turrens JF, Bollo R. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest. 1996;97:562–76.PubMedCrossRef

12.

Kim SJ, Depre C, Vatner SF. Novel mechanisms mediating stunned myocardium. Heart Fail Rev. 2003;8:143–53.PubMedCrossRef

13.

Use T, Makita T, Ureshino H, et al. Milrinone administered before ischemia or just after reperfusion, attenuates myocardial stunning in anesthetized swine. Cardiovasc Drugs Ther. 2006;20:327–34.PubMedCrossRef

14.

Nakashima M, Uematsu T, Kanemaru M. Phase I study of AT- 877 (fasudil hydrochloride) in healthy subjects. Single and multiple administration. Jpn Pharmacol Ther. 1992;20:S1559–1585.

15.

Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43:1029–39.PubMedCrossRef

16.

Hannan LR, John MC, Kouretas PC, Hack BD, Matherne GP, Laubach VE. Deletion of endothelial nitric oxide synthase exacerbates myocardial stunning in an isolated mouse heart model. J Surg Res. 2000;93:127–32.PubMedCrossRef

17.

Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;79:609–34.PubMed

18.

Yada T, Shimokawa H, Hiramatsu O, et al. Beneficial effects of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo. J Am Coll Cardiol. 2005;45:599–607.PubMedCrossRef

19.

Demiryürek Ş, Kara AF, Çelik A, Babül A, Tarakçıogˇlu M, Demiryürek AD. Effects of fasudil, a Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. Eur J Pharmacol. 2005;527:129–40.PubMedCrossRef

20.

Stevens RM, Jahania MS, Mentzer RM, Lasley RD. Sodium-hydrogen exchange inhibition attenuates in vivo porcine myocardial stunning. Ann Thorac Surg. 2004;77:651–7.PubMedCrossRef

Title: Administration of the Rho-Kinase Inhibitor Fasudil Before Ischemia or just After Reperfusion, but not 30 min After Reperfusion, Protects the Stunned Myocardium in Swine
Authors: Itsuko Shibata
Osamu Yoshitomi
Tadasuke Use
Hiroyuki Ureshino
Sungsam Cho
Takuji Maekawa
Tetsuya Hara
Koji Sumikawa
Publication date: 01-08-2008
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 4/2008
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-008-6106-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Administration of the Rho-Kinase Inhibitor Fasudil Before Ischemia or just After Reperfusion, but not 30 min After Reperfusion, Protects the Stunned Myocardium in Swine

Abstract

Objectives

Materials and methods

Results and discussion

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Materials and methods

Results and discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2008

Antiapoptosis and Mitochondrial Effect of Pioglitazone Preconditioning in the Ischemic/reperfused Heart of Rat

Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design

Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit

ACE-inhibitors, Beta-blockers or the Combination in Heart Failure: Is It Just an A–B–C ?

Effects of Folic Acid on Cardiac Myocyte Apoptosis in Rats with Streptozotocin-induced Diabetes Mellitus

Use of Erythropoietin for Cardiovascular Protection